Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
- PMID: 15638853
- DOI: 10.1111/j.1365-2141.2004.05286.x
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
Abstract
Thalidomide and immunomodulatory drugs (IMiDs), which _target multiple myeloma (MM) cells and the bone marrow microenvironment, can overcome drug resistance. These agents also have immunomodulatory effects. Specifically, we have reported that thalidomide increased serum interleukin-2 (IL-2) levels and natural killer (NK) cell numbers in the peripheral blood of responding MM patients. In this study, we investigated the mechanisms whereby IMiDs augment NK cell cytotoxicity. NK cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC) of peripheral blood mononuclear cells cultured with IMiDs were examined in the presence or absence of anti-IL-2 antibody, ciclosporin A or depletion of CD56-positive cells. IMiDs-induced signalling pathways, triggering IL-2 transcription in T cells, were also delineated. IMiDs facilitated the nuclear translocation of nuclear factor of activated T cells-2 and activator protein-1 via activation of phosphoinositide-3 kinase signalling, with resultant IL-2 secretion. IMiDs enhanced both NK cell cytotoxicity and ADCC induced by triggering IL-2 production from T cells. These studies defined the mechanisms whereby IMiDs trigger NK cell-mediated tumour-cell lysis, further supporting their therapeutic use in MM.
Similar articles
-
Lenalidomide and thalidomide: mechanisms of action--similarities and differences.Semin Hematol. 2005 Oct;42(4 Suppl 4):S3-8. doi: 10.1053/j.seminhematol.2005.10.001. Semin Hematol. 2005. PMID: 16344099 Review.
-
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.Cancer Res. 2005 Dec 15;65(24):11712-20. doi: 10.1158/0008-5472.CAN-05-1657. Cancer Res. 2005. PMID: 16357183
-
Mechanism of norepinephrine-mediated inhibition of human NK cytotoxic functions: inhibition of cytokine secretion, _target binding, and programming for cytotoxicity.Brain Behav Immun. 2002 Jun;16(3):227-46. doi: 10.1006/brbi.2000.0615. Brain Behav Immun. 2002. PMID: 12009684
-
NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.Exp Hematol. 2008 Jan;36(1):69-77. doi: 10.1016/j.exphem.2007.08.012. Epub 2007 Oct 23. Exp Hematol. 2008. PMID: 17959301
-
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.Leukemia. 2010 Jan;24(1):22-32. doi: 10.1038/leu.2009.236. Epub 2009 Nov 12. Leukemia. 2010. PMID: 19907437 Free PMC article. Review.
Cited by
-
Understanding of molecular mechanisms in natural killer cell therapy.Exp Mol Med. 2015 Feb 13;47(2):e141. doi: 10.1038/emm.2014.114. Exp Mol Med. 2015. PMID: 25676064 Free PMC article. Review.
-
Natural killer cell biology: an update and future directions.J Allergy Clin Immunol. 2013 Sep;132(3):536-544. doi: 10.1016/j.jaci.2013.07.006. Epub 2013 Jul 30. J Allergy Clin Immunol. 2013. PMID: 23906377 Free PMC article. Review.
-
Multiple Myeloma Therapy: Emerging Trends and Challenges.Cancers (Basel). 2022 Aug 23;14(17):4082. doi: 10.3390/cancers14174082. Cancers (Basel). 2022. PMID: 36077618 Free PMC article. Review.
-
Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.Cancer Immunol Immunother. 2011 Jan;60(1):61-73. doi: 10.1007/s00262-010-0919-9. Epub 2010 Sep 17. Cancer Immunol Immunother. 2011. PMID: 20848094 Free PMC article.
-
Mechanism of action of lenalidomide in hematological malignancies.J Hematol Oncol. 2009 Aug 12;2:36. doi: 10.1186/1756-8722-2-36. J Hematol Oncol. 2009. PMID: 19674465 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
